FBXO32 and cancer: USP19 expression correlates with atrophy markers such as MuRF1 and MAFbx/atrogin‐1 in muscle biopsies of cancer patients, suggesting participation of USP19 to atrophy‐associated protein degradation (Bedard et al., 2015).